What this study is
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell.
What's being tested
- blood draw
Intervention · BIOLOGICAL
Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
Study details
- Official title
- LXR as a Novel Therapeutic Target in DR
- Sponsor
- University of Alabama at Birmingham
- Conditions
- Diabetic Retinopathy
- Enrolling
- 104 people
- Starts
- 2018-01-11
- Est. completion
- 2026-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years – 98 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must either carry the diagnosis of diabetes or be a healthy aged control and b) the patient be willing and have the ability to cooperate with the protocol.
You can't join if
- Exclusion criteria: We will apply the following exclusion criteria: a) evidence of ongoing acute or chronic infection (HIV, Hepatitis B or C, tuberculosis); b) ongoing malignancy; c) cerebral vascular accident or cerebral vascular procedure; d) current pregnancy; e) history of organ transplantation; f) presence of a graft (to avoid any effect of the graft on inflammatory parameters; g) uremic symptoms, an estimated glomerular filtration rate of less than 20 cc/min (by Modification of Diet in Renal Disease equation), or an albumin of less than 3.6 (to avoid malnutrition as a confounding variable); h) be unwilling to abstain from drinking alcohol and i) patients with anemia. Subjects with AMD, glaucoma, uveitis, known hereditary degenerations or other significant ocular complications other than diabetic retinopathy will be excluded.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Alabama at Birmingham
Birmingham, Alabama, United States
- Maria B Grant, MD · Contact2053258674jmoorer@uabmc.edu
- Maria B Grant, MD · Principal investigator
Recruiting
Study team
Sponsor
University of Alabama at Birmingham
Study ID IRB-300000068
Principal investigator
Maria B Grant, MD
University of Alabama at Birmingham
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.